Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Carcinoid Tumor 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 5lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2fluorodopa F 18 2Temozolomide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × aflibercept × Endocrine × Clear all
NCT01782443 2023-08-14

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
19 enrolled 11 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡